NovoCure Ltd Shares Close in on 52-Week High - Market Mover

The shares closed 1.4% below its 52-week high of $220.48, with trading volume lower than its 30 day average

Jun 10, 2021 by Kwhen Finance Editors

NovoCure Ltd Shares Close in on 52-Week High - Market Mover
NovoCure Ltd (NVCR) shares closed today at 1.4% below its 52 week high of $220.48, giving the company a market cap of $21B. The stock is currently up 22.5% year-to-date, up 210.1% over the past 12 months, and up 1487.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 rose 0.3%.

Trading Activity

  • Trading volume this week was 34.6% lower than the 20-day average.
  • Beta, a measure of the stock’s volatility relative to the overall market stands at 1.1.

Technical Indicators

  • The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.
  • MACD, a trend-following momentum indicator, indicates an upward trend.
  • The stock closed below its Bollinger band, indicating it may be oversold.

Fundamentals & Catalysts

  • Over the past 12 months the company generated $43 million in earnings before interest and taxes from $527 million in revenue. It currently holds $864 million in cash and $110 million in debt.
  • Its forward price-to-earnings (P/E) ratio of 7649.99928041368 is higher than its current P/E ratio of 1868.37, implying that analysts are expecting a decrease in earnings.
  • The company's price/earnings-to-growth ratio (PEG Ratio), a widely used indicator of a stock's true value while also factoring in expected earnings growth, currently stands at 76.08. A fairly valued company should have a PEG ratio of 1.0. When a company's PEG exceeds 1.0, it's considered overvalued while a stock with a PEG of less than 1.0 is considered undervalued.
  • The company's debt-to-equity ratio, which measures the extent to which it finances its operations through debt, currently stands at 2.87 which means it currently has $2.87 of debt for every $1 of equity. Generally speaking, a debt to equity ratio below 1.0 is seen as relatively safe, while ratios of 2.0 or higher would be considered risky. Some industries are known for having much higher debt to equity ratios than others.
  • The company's price-to-book ratio, which measures the market's valuation of a company relative to its book value, currently stands at 56.69. This means that the stock is trading at a premium of 57 times relative to the company's book value which reflects the total value of a company's assets that shareholders of that company would receive if the company were to be liquidated.
  • The company's price-to-sales ratio, which shows how much the market values every dollar of the company's sales, currently stands at 40.01.
  • The company's enterprise value-to-revenue multiple, which is often used to determine a company's valuation in the case of a potential acquisition, currently stands at 39.44.

P/E

1868.37

EBITDA

$43M

P/Book

56.69

Mkt Cap

$21B

P/Sales

40.01

Revenue

$527M

EPS (TTM)

0.11

PEG Ratio

76.08

EV/Revenue

39.44

Total Cash

$864M

Debt/Equity

2.87

Forward P/E

7650.00

Current Debt

$110M

Gross Profit

$418M

Dividend Date

-

Earnings Date

2021-07-29

Profit Margin

0.02

Revenue/Share

5.10

Total Revenue

$527M

Enterprise Val

$20B

Put/Call Ratio

0.88

Revenue/Employee

0.00

Market Comparative Performance

  • The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis
  • The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis
  • The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis
NameDoD %ΔYTD %Δ1 Yr %52-Week H %52-Week L %
NovoCure Ltd2.622.5210.1
Dow Jones Industrial Average0.113.528.6-1.141.9
S&P 500 Index0.513.133.5-0.144.8
Health Care1.58.822.3-1.131.3

Peer Group Comparative Performance

  • The company's stock price performance year-to-date lags the peer average by -9.5%
  • The company's stock price performance over the past 12 months lags the peer average by -50.8%
  • The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 305.5% higher than the average peer.
NameMKT CAP (USD)P/EYTD %Δ1 Yr %Δ52-Week H %52-Week L %
NovoCure LtdNVCR1868.422.5210.1
Peer AvgN/A460.824.8426.5
NovoCure LtdNVCR1868.422.5210.1
Novavax, Inc.NVAX-25.388.0356.4
Orchard Therapeutics plc - ADRORTX021.5-32.6
Organovo Holdings IncONVO0-32.81172.3

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?